Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Octreotide acetate

(Sandostatin lar®)

Sandostatin lar®

Drug updated on 12/11/2024

Dosage FormInjection (intramuscular; 10 mg/6 mL, 20 mg/6mL, 30 mg/6mL)
Drug ClassSomatostatin analogs
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the treatment in patients who have responded to and tolerated Sandostatin Injection subcutaneous injection for acromegaly
  • Indicated for the treatment in patients who have responded to and tolerated Sandostatin Injection subcutaneous injection for severe diarrhea/flushing episodes associated with metastatic carcinoid tumors
  • Indicated for the treatment in patients who have responded to and tolerated Sandostatin Injection subcutaneous injection for profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
  • Lanreotide autogel/depot (LAN) maintained normal insulin-like growth factor I (IGF-I) levels in ≥ 70% of patients in one study, with similar results observed in octreotide long-acting release (OCT)-treated patients in a separate study; LAN achieved normal IGF-I levels in ≥ 70% of patients across three studies, reflecting consistent efficacy in IGF-I management among patients with acromegaly.
  • Patient preference data showed LAN was favored over OCT LAR in 4 out of 5 studies, indicating favorable patient-reported outcomes for LAN in terms of treatment experience for acromegaly and neuroendocrine tumors (NETs).
  • Pegvisomant, either as monotherapy or in combination with somatostatin receptor ligands (SRLs), demonstrated similar effectiveness to LAN and OCT in maintaining and achieving normal IGF-I levels in ≥ 70% of patients, suggesting comparable clinical effectiveness across these treatments.
  • The safety profiles of LAN, OCT, and pegvisomant were reported to be similar across extended dosing intervals (EDI) and standard regimens, with no specific adverse effects or safety concerns highlighted in the available data.
  • There is no population types or subgroups information available in the reviewed studies.